Gayed Matthew M, Jew Olivia S, Al-Rohil Rami N, Kheterpal Meenal
Dermatology, Duke University Health System, Durham, USA.
Pathology and Dermatology, Duke University Health System, Durham, USA.
Cureus. 2024 Jun 11;16(6):e62168. doi: 10.7759/cureus.62168. eCollection 2024 Jun.
Xanthoma disseminatum (XD) is a rare, non-Langerhans cell histiocytosis. While treatment is notoriously difficult, 2-chlorodeoxyadenosine (cladribine) has recently emerged as a potential effective therapeutic option. Here, we describe the case of a 65-year-old male with XD who experienced significant cutaneous improvement after cladribine treatment. We also provide an updated literature review on cladribine use in patients with XD in light of reported adverse effects (AEs). While the efficacy of cladribine in XD is clear, no consensus exists for treatment duration and AE management. Hence, we strongly encourage interdisciplinary discourse involving dermatology and oncology in these cases.
播散性黄瘤(XD)是一种罕见的非朗格汉斯细胞组织细胞增多症。尽管治疗难度极大,但2-氯脱氧腺苷(克拉屈滨)最近已成为一种潜在的有效治疗选择。在此,我们描述了一名65岁患有XD的男性患者,其在接受克拉屈滨治疗后皮肤状况有显著改善。我们还根据已报道的不良反应(AE),对克拉屈滨在XD患者中的应用进行了最新的文献综述。虽然克拉屈滨在XD中的疗效是明确的,但在治疗持续时间和AE管理方面尚无共识。因此,我们强烈鼓励在这些病例中开展皮肤科和肿瘤学的跨学科讨论。